BiotechTube

IV efgartigimod

ApprovedRecruiting
1 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Myasthenia Gravis Crisis

Conditions

Myasthenia Gravis Crisis

Trial Timeline

Nov 15, 2024 → Mar 30, 2025

NCT ID
NCT06688253

About IV efgartigimod

IV efgartigimod is a approved stage product being developed by Argenx for Myasthenia Gravis Crisis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06688253. Target conditions include Myasthenia Gravis Crisis.

What happened to similar drugs?

1 of 20 similar drugs in Myasthenia Gravis Crisis were approved

Approved (1) Terminated (2) Active (17)
❌SatralizumabChugai PharmaceuticalPhase 3
🔄tacrolimusAstellas PharmaPhase 3
🔄Tacrolimus capsule + PlaceboAstellas PharmaPhase 3
🔄tacrolimus + placeboAstellas PharmaPhase 3
🔄Cladribine Low Dose + Cladribine High DoseMerckPhase 3
🔄Remibrutinib (Blinded) + Remibrutinib (Open Label)NovartisPhase 3
🔄IptacopanNovartisPhase 3

Hype Score Breakdown

Clinical
20
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06688253ApprovedRecruiting

Competing Products

20 competing products in Myasthenia Gravis Crisis

See all competitors
ProductCompanyStageHype Score
SatralizumabChugai PharmaceuticalPhase 3
32
tacrolimusAstellas PharmaPhase 3
40
Tacrolimus capsule + PlaceboAstellas PharmaPhase 3
40
tacrolimus + placeboAstellas PharmaPhase 3
40
RavulizumabAstraZenecaPre-clinical
33
Cladribine Low Dose + Cladribine High DoseMerckPhase 3
47
Remibrutinib (Blinded) + Remibrutinib (Open Label)NovartisPhase 3
47
Placebo + CFZ533NovartisPhase 2
35
IptacopanNovartisPhase 3
47
mycophenolate mofetil [CellCept] + PlaceboRochePhase 3
40
mycophenolate mofetil (CellCept) + placeboRochePhase 3
40
inebilizumab + IV PlaceboAmgenPhase 3
44
InebilizumabAmgenPhase 2
42
Abatacept InjectionBristol Myers SquibbPhase 1
21
Tolebrutininb + PlaceboSanofiPhase 3
32
Pozelimab + Cemdisiran + Cemdisiran + PozelimabRegeneron PharmaceuticalsPhase 3
44
HIZENTRA ®CSLPhase 2
35
Subcutaneous immunoglobulinsCSLPhase 1
21
Human normal immunoglobulin G (IgG)CSLPhase 3
40
zilucoplan (RA101495)UCBPhase 3
44